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ABSTRACT: We describe 14 patients with 12 novel mis-
sense mutations in ASPA, the gene causing Canavan dis-
ease (CD). We developed a method to study the effect of
these 12 variants on the function of aspartoacylase—the
hydrolysis of N-acetyl-L-aspartic acid (NAA) to aspar-
tate and acetate. The wild-type ASPA open reading frame
(ORF) and the ORFs containing each of the variants were
transfected into HEK293 cells. Enzyme activity was deter-
mined by incubating cell lysates with NAA and measur-
ing the released aspartic acid by LC–MS/MS. Clinical data
were obtained for 11 patients by means of questionnaires.
Four patients presented with a non-typical clinical picture
or with the milder form of CD, whereas seven presented
with severe CD. The mutations found in the mild patients
corresponded to the variants with the highest residual en-
zyme activities, suggesting that this assay can help evaluate
unknown variants found in patients with atypical presen-
tation. We have detected a correlation between clinical
presentation, enzyme activity, and genotype for CD.
Hum Mutat 38:524–531, 2017. Published 2017 Wiley Periodi-
cals, Inc.∗∗
KEYWORDS:Canavan disease;ASPA; ASPA activity; mis-
sense variants; clinical phenotype; functional assay
Introduction
Canavan disease (CD, MIM# 271900) is an autosomal recessive
neurodegenerative disease characterized by spongy degeneration
Additional Supporting Information may be found in the online version of this article.
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of the white matter of the brain [Canavan, 1931; van Bogaert and
Bertrand, 1949]. It is caused by deficiency of the enzyme aspartoacy-
lase (ASPA) [Matalon et al., 1988]. Symptoms usually appear after
normal development during the first months of life and progress
rapidly. They include macrocephaly, hypotonia, loss of muscle con-
trol, feeding difficulties, developmental delay (including motor and
verbal skills), and visual impairment. Somepatients develop seizures
[Traeger and Rapin, 1998; Surendran et al., 2003b]. At this moment,
there is no proven therapy forCD.Use of gene therapy is being inves-
tigated and clinical trials are being performed, some of which show
limited success in slowing the progression of the disease [Leone
et al., 2012]. ASPA is the only known enzyme able to hydrolyze N-
acetyl-L-aspartic acid (NAA) into aspartate (Asp) and acetate. ASPA
deficiency results in accumulation of NAA in body fluids. Elevation
of NAA levels in urine is the biochemical hallmark of CD.Molecular
analysis of ASPA gene (MIM# 608034, NG 008399.1) is the confir-
mative test. This gene is located on chromosome 17 (17p13.2). It is
composed of six exons and comprises about 30 kb. More than 100
mutations in ASPA have been submitted to the Leiden Open Vari-
ation Database (LOVD), including deletions, missense mutations,
andnonsensemutations (http://www.lovd.nl/ASPA).CDcarrier fre-
quency among Ashkenazi Jewish populations is relatively high: one
in 30 to one in 60, corresponding to an incidence of one in 5,000
to one in 6,700 [Kronn et al., 1995; Matalon et al., 1995; Feigen-
baum et al., 2004]. Only two mutations are responsible for about
98% of CD alleles in this population [Matalon, 1997]. Themutation
c.854A>C, p.Glu285Ala is responsible for about 84% of CD alleles,
whereas the mutation c.693C>A, p.Y231X is found in about 14%
of CD alleles. Both mutations are associated with a severe pheno-
type. The overall incidence is much lower (one in 200,000 to one to
400,000). Here, the most common mutation responsible for about
40%–48% of the CD alleles is c.914C>A, p.Ala305Glu. This mu-
tation has been associated with both severe and mild phenotypes
[Shaag et al., 1995].
ASPA (EC3.5.1.15) is a dimeric metalloenzyme composed by
37 kDamonomers (313 amino acid residues). It is mainly present in
C© 2017 The Authors. ∗∗Human Mutation published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
brain white matter (mainly oligodendrocytes) and kidney [Baslow
et al., 1999; Sommer and Sass, 2012]. The crystal structure of ASPA
has been resolved (Bitto et al., 2007; Le Coq et al., 2008). ASPA
binds one atom of Zn per monomer [Le Coq et al., 2006] and this
metal is necessary for the enzyme reaction. The amino acid residues
involved in Zn binding are His21, Glu24, and His116. The catalytic
site is composed of residues Arg63, Asn70, Arg71, Tyr164, Arg168,
Glu178, and Tyr288. Residues Arg168 and Tyr288 stabilize the bind-
ing of NAA to ASPA. It was shown that due to rare codon usage,
eukaryotic expression systems need to be used to properly study en-
zyme variants [Wang and Viola, 2014]. The vast majority of ASPA
mutations that have been overexpressed in COS or human embry-
onic kidney (HEK)293 cells present very low enzyme activity (lower
than 5% of wild-type (WT)) [Janson et al., 2006; Sommer and Sass,
2012; Surendran et al., 2003a].
In this article, we report a method for the characterization of
missense variants inASPA gene transiently transfected intoHEK293
cells. A total of 14 patients (corresponding to 12 missense variants)
were included in our study.
Material and Methods
Patients, Sample Collection, Mutational Analysis,
and Inclusion Criteria
From 1.1.2002 to 31.12.2015 genomic DNA was isolated from
blood of patients suspected of CD on basis of clinical and biochemi-
cal findings, such asmacrocephaly, hypotonia, developmental delay,
and increased urinary excretion of NAA. To analyze the coding re-
gion of the ASPA gene, the six exons and intron boundaries were
amplified by PCR. Sequence analysis was performed in both direc-
tions with ABI Prism BigDye Terminator Cycle Sequencing Ready
Reaction Kits, in an ABI PRISM 3130xl Genetic Analyzer (Applied
Biosystems, FosterCity,CA). Sequenceswere comparedwith the ref-
erence sequence from the GenBank (NG 008399.1) using Mutation
Surveyor (Softgenetics, State College, PA). Nucleotide numbering
of variants reflects cDNA numbering with +1 corresponding to the
A of the ATG translation initiation codon in the reference sequence
(NM 000049.2). Fourteen patients, harboring missense mutations
not described in literature, were selected for this study. Physicians
following these patients were invited to fill in a questionnaire cover-
ing clinical signs, clinical course, motor and cognitive development,
NAA levels, and radiographic investigations. Eleven questionnaires
were received. Patients were numbered 1–11 and divided into two
groups based on their ability to achieve (minimal) speech and their
ability to walk.
Construction of the ASPA Expression Vector
and Site-Directed Mutagenesis to Introduce Variants
The human ASPA gene (NM 000049.2) encoding the enzyme
ASPA was amplified by PCR using the primers ASPA Clon F, con-
taining a restriction site for the enzyme Asi SI, and ASPA Clon R,
containing a restriction site of the enzyme Rsr II (Supp. Table S1).
After purification, the amplified fragment and the pCMV6 vector
(Origene, Rockville, MD) were digested with the enzymes Asi SI
(New England Biolabs, Ipswich, MA) and Rsr II (New England
Biolabs) and ligated, in frame with mGFP. The final construct was
used as a template to introduce the following mutations: c.70G>A
(p.Glu24Lys), c.89T>C (p.Leu30Pro), c.170C>T (p.Ala57Val),
c.188G>C (p.Arg63Thr), c.206T>G (p.Leu69Arg), c.302G>T
(p.Gly101Val), c.385G>A (p.Glu129Lys), c.509T>C (p.Ile170Thr),
c.539G>T (p.Gly180Val), c.610G>C (p.Asp204His), c.743A>G
(p.Gln248Arg), c.854A>C (p.Glu285Ala), c.857C>A (p.Ala286Asp),
and c.914C>A (p.Ala305Glu) by site-directed mutagenesis using
the primers listed in Supp. Table 1, as described previously [Betsalel
et al., 2012]. The authenticity of mutagenesis and cloning was
verified by DNA sequencing.
Overexpression of ASPA Alleles in HEK293 Cells
HEK293 cells were cultured to 70% confluency and used for
transient expression of the obtained constructs. For the transfec-
tions, 12 μg of plasmid DNA was incubated with 60 μl of Fu-
gene (Promega, Madison, WI) at room temperature for 15 min in
serum-free DMEM medium (Thermo Fisher Scientific, Waltham,
MA). The complex was applied to the cells. Cells transfected ei-
ther with WT pCMV6-ASPA (from here on related to as WT), the
empty vector (mock transfected) as well as untransfected cells were
included as controls. The most common variants found in patients
from Ashkenazi Jewish background (c.854A>C, p.Glu285Ala) and
in non-Jewish populations (c.914C>A, p.Ala305Glu) were also in-
cluded as controls. Fluorescent microscopy was used to estimate
transfection efficiency. Cells were harvested 48 hr after transfection,
flash-frozen, and stored at –80°C until further use. Transfections
were performed in triplicate.
Functional Analysis of ASPA Variants by Novel Enzyme
Assay
A novel enzyme assay was developed in which the production
of Asp from NAA was measured by LC–MS/MS. Cell pellets were
suspended in 200 μl of 200 mmol/l Tris buffer (pH = 8.5) con-
taining 0.5 mmol/l phenylmethylsulfonyl fluoride. Cell membranes
were disrupted by three freeze–thaw cycles. The supernatant was
collected following 5 min centrifugation at 13,000g (11,000 rpm) at
4°C. Approximately 10 μg of protein (1 μg for WT) was incubated
for 30 min at 37°C in 200 μl of 200 mmol/l Tris buffer (pH = 8.5)
containing 1.25 mmol/l of NAA. The reaction was terminated by
placing the samples on ice and adding 20 μl 200 mmol/l nonafluo-
ropentanoic acid. After 25 μl of [D3]-aspartic acid was added as an
internal standard, the lysates were pipetted on a molecular weight
cut-off filter (mw 10.000; Amicon; Millipore, Billerica, MA) and
centrifuged for 10 min at 20,000g (14,000 rpm) at 4°C. Km value
for WT was found to be 0.2 mmol/l, in agreement with previously
published data [Le Coq J. et al., 2006].
The aspartic acid formed was measured by positive electrospray
triple quadrupole tandem mass spectrometry (API 5000; Applied
Biosystems) coupled to a Shimadzu Nexera HPLC (Kyoto, Japan).
Five microliters of the incubation mixture was separated on a Sym-
metry Shield C18 analytical column (3.5 μm, 3.0 × 100 mm2;
Waters, Milford, MA) using a mobile phase containing 5 mmol/l
nonafluoropentanoic acid. The gradient was started at 0% acetoni-
trile for 5min. In 4min, the acetonitrile content of themobile phase
was increased from 0% to 50%. Mass transitions m/z 134.1 → 88.1
and 137.1 → 91.1 were used for unlabeled and [D3] labeled aspartic
acid. Intra-assay variations were 11% for WT and 4% for a variant
with low activity (n = 6). Protein content was measured using the
Bicinchoninic acid method (Sigma–Aldrich, St Louis, MI). Bovine
serum albumin was used as the standard. All determinations were
performed in triplicate. The amounts of aspartic acid measured in
WT and variant ASPA enzymes were corrected for endogenous as-
partic acid andendogenousASPAactivity by subtracting the amount
of aspartic acid measured in mock-transfected cells.
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Western Blot
To confirm the presence of ASPA protein in the transfected cells,
aWestern blot was performed. Cell pellets were resuspended in urea
lysis buffer (10mmol/l Tris HCl, 8mol/l urea, 100mmol/l NaCl, pH
8.0). After DNA shearing using a 29 gauge needle, protein concen-
trationwas determined as described above and 30μg of total protein
was separated in a 12% stain-free SDS gel (Bio-Rad Laboratories,
Hercules, CA). Proteins were transferred onto a polyvinylidenfluo-
ridemembrane (Bio-Rad) using a Trans-Blot TurboTransfer System
(Bio-Rad). Immunodetection was performed using a primary anti-
body (rabbit) directed at the GFP tag (ab290; Abcam, Cambridge,
UK) and a secondary anti-rabbit antibody (PO448; Dako, Glostrup,
Denmark). Immune complexeswere detected by enhanced chemilu-
minescence (Lumilight Plus), according to themanufacturer’s speci-
fications (Roche, Indianapolis, IN). Images were acquired in a CCD
(charge-coupled device) imager ChemiDoc XRS (Bio-Rad) using
the Image Lab software (Bio-Rad).
Structural Modeling
The crystal structure of the WT human ASPA (PDB ID:2O4H)
was used as a template to generate structures for the variants ad-
dressed in this study using the online structural predictor SDM
(http://mordred.bioc.cam.ac.uk/˜sdm/sdm.php).Molecular graph-
ics and analyses were performed with the UCSF Chimera package.
Chimera is developed by the Resource for Biocomputing, Visualiza-
tion, and Informatics at the University of California, San Francisco
(supported by NIGMS P41-GM103311) [Pettersen et al., 2004].
Results
Genotypic Characterization of Patients
DNA sequencing was used to confirm diagnosis of CD in 84
patients in our laboratory. Twelve novel missense variants were de-
tected in 14 patients, whowere selected for this study: nine homozy-
gous and five compound heterozygous patients. Figure 1 depicts the
structure of the ASPAmonomer with the location of the 12 affected
residues as well as the two most common variants. All mutations
result in the replacement of amino acid residues that are very con-
served across species. The identified mutations have been included
in the Leiden LOVD (http://www.lovd.nl/ASPA). A scheme of all
mutations reported in ASPA gene is depicted in Figure 2.
Clinical Features of Patients with New ASPA Mutations
Eleven out of the 14 questionnaires sent out to the clinicians
were returned. In one case, the clinician could not be contacted, the
other two did not respond. Eleven out of 14 Canavan patients (six
males) with new missense mutations were evaluated. First signs in
this patient group appeared from birth (macrocephaly) up to an
age of 6 years and 10 months. Follow-up time was 6 months to
36 years (range 6–432 months, average 153, median 120 months).
Four patients were lost to follow up (at 6, 24, 264, and 432 months);
two of these had died. At the last follow up, six patients were still
alive; of one this is unknown. First signs (provided for nine out
of 11 patients) included developmental delay, hypotonia (head lag
(n = 4), poor/no head control (n = 4)), decreased contact (n = 2),
motor retardation (n = 1),movement abnormalities (n = 1), epilepsy
(n = 1), intellectual disability (n = 1), loosing skills (n = 1), and
behavioral problems (n = 1). Patients were categorized into two
groups based on clinical presentation. The atypical/mild group was
composed of patients 1–4. Patients 5–11 were part of the severely
affected group.
Clinical course in patients was unknown (n = 1), stable (n = 2),
slowly progressive (n = 8), or rapidly progressive (n = 1). Rapid de-
terioration was described in four patients and was determined by
the development of seizures in patients with either a slowly pro-
gressive (patients 2, 5, and 8) or rapidly progressive disease course
(patient 9). Other signs during the course of disease were optic at-
rophy (one out of seven), developing spastic tetraparesis (three out
of six), dysarthria (two out of 10) and nystagmus (one out of 10),
amblyopia (one out of 10) and intermittent exotropia alternans (one
out of 10).
Head circumference was normal in patients 1, 2, 3, and 5. Macro-
cephaly was seen in all other patients with a severe phenotype;
patient 10 was normocephalic at birth and developedmacrocephaly
with time. In nine out of 11 patients, height was within the nor-
mal range (–2SD to +2SD). Seven patients had a normal weight,
whereas one was overweight (patient 3). No information on weight
was available for two patients.
Seizures were present in four out of 11 patients, starting from
an age of 3 months to 8 years. Seizures were treated with either
valproate or phenobarbital and topiramate (no information in one).
Twopatients (number 5 and10) receiveduncommondrugs (lithium
citrate or acetazolamide) without effect.
Cognition was affected in all patients. Cognition was reported as
severely deficient in seven patients. Five patients showed no speech
development at all. In patients 1–4 (mild types), speech was less
severely affected, with two of these patients receiving special or
supportive education, the latter attending normal school (no in-
formation from patient 3). Of the severely affected group, patient
10 received special education with mild deficient cognition. In all
other patients, no education was possible.
All except four patients showed abnormal motor development.
Patients 1, 2, and 3 were able to walk without support. Patient 4
walkedwith support until the age of 13 years and becamewheelchair
dependent. All patients classified as severe (patients 5–11) showed
a severe motor impairment and did not achieve walking. These
patients also suffered from poor to no head control.
EEGs were performed in eight out of 11 patients. In five patients,
EEGs were diffusely slow; in one patient, paroxysmal features were
observed, with a normal background activity, and in another, diffuse
dysrhythmic changes (patient 2). In one patient, clinical seizures
were observed but could not be confirmed on EEG. No EEGs were
performed in the other three patients because they did not show
clinical evidence of seizures.
An MRI was performed in 10 out of 11 patients. In four patients,
an MRS (patients 1, 9, 10, and 11) was included in the same investi-
gation. Patients categorized as mild or atypical presentedMRI/MRS
not typical for classical Canavan’s disease, in agreement with their
clinical presentations.
A summary of genotype and phenotypic presentation of disease
for all patients is described in Table 1.
Functional Analysis of Novel ASPA Variants
Enzyme activity was determined in cell lysates of HEK293 trans-
fected with the constructs described. Cell lysates transfected with
WT ASPA displayed an activity of 6,180 ± 1,223 nmol Asp/h/mg.
This activity was 200-fold higher than the mock transfected lysates.
Activities are expressed as % of WT activity. The majority of the
studied variants presented with enzyme activities lower than 1% of
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Figure 1. Schematic and structural representation of the ASPA monomer with the location of the amino acid residues addressed in this study.
The structural image was generated using the crystal structure of ASPA (PDB ID: 2O4H), obtained using the UCSF Chimera package. Chimera is
developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS
P41-GM103311).
the WT. The common variant p.Glu285Ala presented an activity of
2.7 ± 0.7% of the WT activity. The variant p.Ile170Thr presented
5.5 ± 2.8% of residual activity. The variant with the highest activity
detected (12.4 ± 2.8%) was p.Asp204His.
Western Blot
Sincemost of the variants studiedpresentedwith very low enzyme
activities, aWestern Blot was performed to verify whether all variant
proteinswere expressed.All variants presenteddetectable expression
of ASPA with no major differences concerning level of expression
when compared to the WT (Fig. 3).
Structural Analysis
Structuralmodels for the 12novel variants studiedwere generated
(using the prediction tool SDMas described in sectionMaterials and
Methods) and compared with the WT structure. Overall the amino
acid replacements did not cause major structural changes. This was
also observedwhenWijayasinghe et al. (2014) crystalized four ASPA
variants. Regarding variant p.Glu24Lys, amino acid residue Glu24
is one of the Zn binding residues. Replacement of the residue Glu
by Lys will change the local polarity of the residue and probably
interfere with the bond stability of the cofactor, which could explain
the decrease in enzyme activity. In addition, variant p.Glu24Ala
resulted in complete ablation of enzyme activity [Le Coq et al.,
2008]. Replacement by Asp leads to decreased levels of bound Zn
andno enzyme activity [LeCoq et al., 2008]. The variant p.Glu24Gly
has been reported in heterozygous state in one patient (the other
allele harboring c.514C>A, p.Pro181Thr) with classical CD [Zeng
et al., 2002].
Regarding variant p.Leu30Pro, the amino acid Leu presents the
highest propensity to form α-helix structures and provide helix
stability. Indeed, Leu30 is located in α-helix 1. On the contrary,
Pro cannot form α-helices. It can only be incorporated in the
first turn of the helix due to the ring structure, which is a helix
breaker. This amino acid replacement is likely to cause a structural
change in ASPA, which can explain the absence of enzyme activ-
ity. It was shown before that replacement of Leu by Pro leads to
unfolding of helical regions [O’Neil and DeGrado, 1990; Strehlow
et al., 1991].
The variant residue of p.Ala57Val, Ala57 is located on the first
turn of α-helix 2. Replacement by Val will not dramatically change
the properties of the residue. However, Val residues are most often
found in β-sheet structures and replacement of Ala by Val results
most likely in structural changes that can explain the absence of
enzyme activity observed for the p.Ala57Val variant.
Regarding variant p.Arg63Thr, amino acid residue Arg63 is part
of the catalytic center of ASPA and is important for stabilization of
the substrate, meaning that replacement of that residue will likely
result in an inactive enzyme, as observed.
In the variant p.Leu69Arg, replacement of the branched non-
polar amino acid residue Leu by the polar amino acid Arg with a
longer side chain will likely have impact on the overall structure of
the protein and result in a decreased enzyme activity.
The affected residue in variant p.Gly101Val, Gly101 is very con-
served in eukaryotes. Val is an amino acid residue with a larger side
chain, which can result in a steric hindrance. In our system, this
variant presented with no enzyme activity.
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Figure 2. Schematic representation of the ASPA gene and the distribution of all published mutations (as of September 2016). These mutations
are part of the mutation database LOVD (http://www.lovd.nl/ASPA). Variants located in exonic regions are in black, variants in intronic regions are
in gray. Novel variants addressed in this study are represented in bold. Large deletions are depicted in the box.
Concerning the variant p.Glu129Lys, residue Glu129 contributes
to intra-monomer stability by establishing hydrogen bonds with
Thr166. Replacement by Lys will hinder the formation of these
stabilizing bonds, which can explain the observed inactivation.
The variant p.Ile170Thr affects residue Ile 170, which is part
of α-helix 7. The in silico model predicts that the replacement of
Ile170 by Thr results in disruption of the α-helix. Although this
replacement results in a decrease in enzyme activity (about 6% of
WT), it is important to consider that among the studied variants
this one presented with the second highest residual enzyme activity.
About variant p.Gly180Val, replacement by Val will likely have an
impact on protein structure due to the addition of the side chain.
Variant p.Asp204His affects the very conserved (eukaryotes)
Asp204. This residue is located at the surface of the protein. This
variant was used for in silico secondary structure prediction and
reported to cause conformational changes in the protein [Shinar
et al., 2004].
Regarding variant p.Gln248Arg, Gln 248 is located in the dimer
interface. Arg presents completely different properties, changing the
size and polarity of the side chain of this residue. This replacement
may affect the formation of the dimer, which can explain the inac-
tivation of ASPA.
The variant p.Ala286Asp affects a highly conserved amino acid
residue in eukaryotes. Ala presents with a small non polar side chain.
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Table 1. Genotypic, Clinical, and Biochemical Data of Patients with Novel ASPAMutations∗
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Macrocephaly – – – + – + + + + + +
Epilepsy – – – + + – – – + + –
Mental delay + +d ++e +++ +++ +++ +++ +++ +++ + +++









Sounds Sounds Sounds Sounds Sounds No ?f
Motor delay – + – + +++ +++ +++ +++ +++ +++ ++
Poor head
control
– – – + + + + + + + +
No walking
achieved








134 432g 120 372 109 24g 264g 15 92 120 6g
Enzyme activity
(% of WT) in
HEK293
transfectantsh
5.5 ± 2.8 <1% 5.5 ± 2.8 12.4 ± 2.8 <1% <1% <1% <1% <1% <1% <1%
∗of whom we received questionnaires. Clinical data from homozygous patients 12 (c.188G>C, p.Arg63Thr), 13 (c.206T>G, p.Leu69Arg), and 14 (c.857C>A, p.Ala286Asp) are
not available.
Notes: A + indicates the presence and a – indicates the absence of the phenotype. For mental and motor delay + means mild, ++ is moderate, and +++ means severe.
aPatients are siblings.
bOne variant is shown for homozygous patients. Novel variants are highlighted in bold.
cInfancy.
dAttended normal school with support.
eAutism.
fDid not achieve normal milestone age.
gLost to follow up at.
hFor heterozygous patients, the activity indicated corresponds to the variant in bold.
Replacement by Asp results in a dramatic increase in the size of the
side chain. This could explain the non-detectable enzyme activity.
Discussion
Diagnosis of inborn errors of metabolism (IEM) has come a long
way. For highly incapacitating diseases, like CD, with no available
therapy the option of prenatal diagnosis is often very important
for families with affected individuals. To prevent false positive or
negative results, it is of utmost importance that the method used
to diagnose the disorder is both accurate and specific. For CD, his-
torically prenatal diagnosis was based on enzyme determinations
in amniocytes. The extremely low ASPA activity in these cells rep-
resents an analytical challenge and unfortunately led to misdiag-
nosed cases in the past [Matalon et al., 1992]. The introduction
of stable isotope dilution analysis of amniotic fluid in our labo-
ratory in 1991 [Jakobs et al., 1991] offered a more reliable tech-
nique for this purpose. Later DNA analysis replaced these methods
for the majority of prenatal diagnoses. Nowadays, next-generation
sequencing is becoming more and more a first step in the diag-
nosis of patients with disorders of unknown etiology including
so far undetected IEM. This results in the identification of novel
variants and mild or atypical phenotypic presentations. There-
fore, a functional test is necessary to understand the significance
of novel missense variants. We developed an overexpression system
to characterize missense variants in the ASPA gene. This system
bypasses the need for additional material from patients and can also
be used to confirm pathogenicity of variants identified in familial
cases.
More than 100 mutations have been described in the ASPA gene.
We developed a public database for these variants and included all
published and novel variants (http://www.lovd.nl/ASPA). We ana-
lyzed the effects of 12 novel ASPA missense mutations (detected in
a total of 14 patients) as well as two common missense mutations
(p.Glu285Ala and p.Ala305Glu). The 14 variants were transiently
transfected into HEK293 cells, which are considered the most suit-
able system to study ASPA variants because it ensures the availability
of all necessary codons [Wang and Viola, 2014].
The activity measured for the WT (6,180 ± 1,223 nmol
Asp/hr/mg) and for the variant p.Glu285Ala (about 2% of WT)
match the activities described in the literature [Kaul et al., 1994;
Moore et al., 2003; Sommer and Sass, 2012], validating ourmethod.
Different phenotypic presentations have been described for CD.
The classical severe form is the most common, but milder CD pre-
sentations have also been reported [Toft et al., 1993; Shaag et al.,
1995; Zafeiriou et al., 1999; Tacke et al., 2005; Yalcinkaya et al., 2005;
Janson et al., 2006; Velinov et al., 2008; Delaney et al., 2015; Nguyen
and Ishak, 2015; Sarret et al., 2016]. In our study, four patients
showed an atypical or mild presentation (patients 1–4), whereas the
remaining seven presented with the classical CD phenotype. In our
study, we observed a correlation between the mutations detected in
the mild cases and the variants with the relatively higher enzyme
activities (p.Ile170Thr, p.Asp204His).
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Figure 3. Expression levels of ASPA proteins in fusion with mGFP
transiently transfected into Human Embryonic Kidney cells (HEK293)
monitored byWestern blot analysis after SDS-PAGE. Thirty micrograms
of total protein was loaded per lane. An antibody against mGFP was
used as primary antibody. The arrow points to the ASPA-mGFP fusion
protein. The ∗ indicates free mGFP.
Based on the functional studies, the biochemistry and the clinical
information, we classify the following 10 variants as pathogenic
mutations: p.Glu24Lys, p.Leu30Pro, p.Ala57Val, p.Arg63Thr,
p.Leu69Arg, p.Gly101Val, p.Glu129Lys, p.Gly180Val, p.Gln248Arg,
and p.Ala286Asp. All these variants were identified in patients
with a severe phenotypic presentation of CD and showed less than
1% of WT ASPA residual activity in our system. The homozygous
p.Asp204His mutation was detected in a 31-year-old patient (pa-
tient 4). This variant showed a relatively high residual ASPA activity
(12%) in our functional assay. The clinical features did fit with mild
CD (macrocephaly, MRI characteristic for CD) and also largely
increased NAA levels in urine were detected. We believe that variant
p.Asp204His is responsible formilderCDpresentation and therefore
we also classify this variant as pathogenic. The variant p.Ile170Thr is
more difficult to classify. The p.Ile170Thr was found in two patients
with only a very mild increase of NAA in urine without further
hallmark signs of CD. The two patients harboring this variant are
currently 10 (patient 3) and 11 years old (patient 1). Because in the
two other mild patients (patient 2 and 4), the clinical presentation
becamemore severe with age (around 30 (patient 2) and 14 (patient
4)), the clinical phenotype may change with time. For the time be-
ing, we propose to consider this as a rare variant of unknown clinical
significance. Identification of more patients and the additional data
from disease progression of these two cases will help to assess the
clinical significance of this variant. The mild presentation observed
for patient 2 could potentially be explained by variant c.432G>A.
This variant was described before [Schober et al., 2011]. Nucleotide
c.432 is the last base (3′end) of exon 2 and it will most likely affect
the splice donor of intron 2, probably resulting in skipping of exon
2 and possibly allowing a small percentage of correctly transcribed
ASPA mRNAs. The mild phenotype observed in this patient could
be explained by the correct WT splicing of a small amount of
ASPA mRNA product as described for other splice mutations [van
Berge et al., 2012] but mRNA studies are necessary to confirm this
hypothesis.
We report a correlation between ASPAmutation, enzyme activity
and clinical presentation of CD. Such a correlation was observed
before for CD [Zano et al., 2013]. We describe 14 new patients with
a total of 12 novel missense variants not characterized before. By
the use of our functional assay, we have confirmed for 11 out of 12
that the variants are pathogenic. Three of the patients that presented
with milder phenotype harbored the mutations that presented with
the highest residual activities in our assay. It is remarkable that a
residual activity of about 10% of WT can already be associated
with a milder form of CD. This observation suggests that a slight
increase in activity can already have a big impact on the quality of
life of patients and families that have to deal with CD. This newly
developed functional assay is implemented in our diagnostic facility
and will improve not only diagnostics for new cases, but it can also
be helpful to identify potential therapies.
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